Medicinal cannabis industry news, information and insights
We're back!
After a short illness we are back and ready to smell the flowers
What's inside tomorrow's newsletter?
1. Cannabis prescriptions dropped 30% in April ⬇️
2. Avecho capital raise fails 💸
3. Cannabis improves your wellbeing 🧘
4. Little Green Pharma flies high (😉) in France 🇫🇷
Hi Greenies, due to illness I'm not able to complete tomorrows newsletter. I'm going to roll the stories into Thursdays newsletter.
Apologies if anyone feels let down...
Just chopped and packed another The Greenfields
What's inside?
1. Will Cannaponics crowd funding go up in smoke? 🔥
2. CBD anti-inflammatory trial results 💊
3. Nimbin Mardi Grass 2023
Just rolled tomorrows The Greenfields News...
What's inside?
1. Cann Group’s growing revenues 📈
2. Emyria shares drop 12.00% after raising $2.5 million 📉
3. Little Green Pharma grows operating losses to $10 million 💰
4. Avecho partnerships jump shares 12.00% 🦘
Lots of quarterly reports to go over... We hope you are excited
🌿 Morning Greenies
Are you hungover? Or are you feeling great because you had cannabis instead of alcohol last night?
The Greenfields Dr. Lenny has spoken out against inflated THC results
When asked how realistic 40% THC is they said:
"I think it would be a pretty fu**ed up looking flower"
The Australian Medicinal Cannabis Association and the Society for Cannabis Clinicians Australian Chapter have proposed a draft code of conduct to regulate telehealth consultations for medicinal cannabis. The code includes recommendations such as in-person consultations being the preferred method, with telehealth only recommended for patients with no local access or difficulties attending a clinic in-person.
The code also suggests that patients have in-person follow-up consultations until a safe dosage is found, at which point it can be reduced to every 3-6 months. Prescribers are required to disclose any financial relationships they have with the clinic or cannabis industry to avoid conflicts of interest. Adoption of this code could make accessing medicinal cannabis harder and more expensive for patients.
Did you miss yesterdays newsletter?
Don't worry, we've got ya:
PLUS: Is TYSON 2.0 coming to AUS?👂, Emyria's high CBD capsule, ECS Botanics grow revenue
🌿 Morning Greenies 🌅
It's Friday! Are you drinking alcohol tonight, or consuming cannabis?
Did you sign up for The Greenfields but can't find todays email?
Check your promotions or spam folder
Make sure you move it into your primary inbox so you get it next time:
New York is potentially losing out on $2.6 billion in tax revenue over the course of 8 years due to a slow pace of licensing and opening cannabis dispensaries. According to a report by MPG Consulting, the state needs around 900 dispensaries to supply its demand, but only 36 are set to open this year. The delays in licensing are due to capital requirements and inspections, permitting, and hiring processes taking up to 9 months to a year to complete.
MPG Consulting recommends that existing licensed medicinal cannabis operators be allowed access to the recreational market to quickly increase the number of dispensaries. However, some entrepreneurs, businesspeople, and stakeholders have launched a lawsuit alleging that the state should open up licensing to more people than just social equity applicants.
Endometriosis can cause significant pain and discomfort for sufferers, affecting their quality of life. However, there may be hope on the horizon. Western Sydney University has been granted $660k to investigate the potential benefits of medicinal cannabis for treating endometriosis. This exciting study will explore whether cannabidiol isolate or balanced THC/CBD oil can help reduce pelvic pain and other symptoms. Learn more about this exciting research and how it may benefit women with endometriosis.
🌿 Morning Greenies
Don't forget to take your medicine
Just rolled another The Greenfields and it's a big one
What's inside?
1. Viroid threatens cannabis industry 🦠
2. Is TYSON 2.0 coming to Aus? 👂
3. Photos of People (or Cats) Surrounded by Cannabis 📸
4. ECS Botanics quarterly receipts up 256% 📊
5. Emyria’s high (😉) CBD capsule 💊
If you don't subscribe you won't (h)ear the news 👇
Are we heading for a medicinal cannabis shortage in Australia?
From July 1st, imported medicinal cannabis will have to be grown at a TGA approved site or be grown at a site licensed under similar regulations to the country it is grown in. This means suppliers may face fines and non-compliant products could be removed from pharmacy shelves.
With over 90% of medicinal cannabis consumed in Australia being imported, the question is whether the local industry has enough capacity to fill the gap. Are patients being warned of non-compliant products and given an opportunity to switch to a compliant substitute before the July 1 deadline?
Creso Pharma's (ASX:CPH) Canadian cannabis business Mernova has achieved its very first cashflow positive quarter, thanks to a revenue increase of 46% to $1.5 million.
With its largest-ever purchase order of $350k and increasing expansion and growth, Mernova's success is an inspiring accomplishment for the company
Morning greenies 🌿
We hope you are refreshed after the public holiday
Althea Group (ASX: AGH) had record cash receipts of $9.24 million and their first monthly profit in the March quarter of 2023.
Their recreational division, Peak, grew by an impressive 55%, while their medicinal group only saw an 11% increase.
Peak is a B2B cannabis processing business that creates product solutions
💊 NSW's new Premier Chris Minns has shown a willingness to shift his stance on cannabis law reform based on changing circumstances. In the past, he defended legalizing recreational cannabis as a way to reduce organized crime and promote safer use. However, he later abandoned this idea before the upcoming election in 2023. Minns' latest update on his views is that the widespread availability of medicinal cannabis has opened up new avenues for pain relief and symptom management. He seems to be keeping an open mind about re-examining cannabis reform, so we'll be waiting to see how this develops.
Little Green Pharma has successfully delivered the first cannabis shipment to Ilios Sante in Germany as part of their $2.3 million deal.
80% of the minimum purchase under the deal will occur in year two. After working diligently to finalize licenses and quality arrangements, the two companies have completed their first shipment
Cann Group, a leading producer of medicinal cannabis in Australia, is making strategic moves to take advantage of the growing market opportunity.
Despite declining to set a timeline for positive cashflow, they are ramping up production at their Mildura facility in anticipation of increased demand for locally grown cannabis. This comes after the TGA announced changes to import quality requirements, set to take effect on July 1st. While their S3 sleep treatment had failed trials earlier this year, Cann Group remains in discussions with partner Haleon about its next steps. Stay tuned for updates!
TYSON 2.0 cannabis could be coming to Australia
Intercure Ltd have been granted exclusive distribution rights for TYSON 2.0 in Israel, Australia, United Kingdom, Germany and other EU countries
Would you buy celebrity cannabis?
Did you miss yesterdays Greenfields?
Don't worry, we've got ya:
PLUS: Cann won't set positive cashflow timeline 💸, Creso Pharma positive Canada cashflow, Can cannabis help with endometriosis? Who started 420? and Photos of People (or Cats) Surrounded by Cannabis
Just packed tomorrows newsletter
We weren't clever enough to come up with something clever for 420, so you just got a bit extra tomorrow:
1. NSW Premier chicken on drug law reform 🐣
2. Will Cann Group ever reach positive cashflow? 💸
3. Photos of People (or Cats) Surrounded by Cannabis 📸
4. Creso Pharma positive Canada cashflow 🇨🇦
5. Who started 420? 4️⃣ 2️⃣ 0️⃣
When it's Tuesday morning and everyone else is reading The Greenfields newsletter except you because you didn't subscribe 👇
Just rolled tomorrows The Greenfields newsletter
What's inside?
1. Code targets medicinal cannabis telehealth 📞
2. Little Green Pharma ships to Germany 🇩🇪
3. Legalise Cannabis NSW wins a seat 🪑
4. CBD vapes being pushed on TikTok 🕰
Not a subscriber? Oh well...
A reader asks: Do terpenes really have an effect when using cannabis?
When plants are challenged by weather, or pests (including cannabis consumers), they produce a suite of protective chemicals called secondary metabolites. Sometimes, these secondary metabolites have biological functions.
Well known secondary metabolites are morphine and codeine for pain relief. Terpenes are known as the 'fragrant' class of secondary metabolites.
Cannabis is especially rich in terpenes. There are at least 150 different terpenes in cannabis, although most are lost when the leaves are dried or stored.
The most popular idea about terpenes in cannabis is the 'Entourage Effect'. This theory suggests that terpenes work with cannabinoids to increase their effects. However, this idea isn't scientifically proven yet.
It comes from cannabis users believing that different strains of cannabis produce different effects. One strain is calming and another one excites. In one of the few scientifically conducted studies into the Entourage Effect cannabis terpenes did not enhance pain relief effects of cannabis in rats.
Of the minimal research we have some promising cannabis terpenes are β-caryophyllene, which activates the cannabinoid receptor and enhances your high. α-pinene and β-pinene are thought to directly influence the neurotransmitter pathway for muscle control, learning, memory and attention.
There is absolutely no doubt that some plant terpenes have a medical effect. For example, Taxol, isolated from the bark of the Pacific yew tree, is highly effective in treating many cancer types.
So, it is also likely that some of the 150 terpenes found in cannabis are biologically active. However, more rigorous scientific research needs to be conducted.
Another The Greenfields newsletter has been rolled and is ready to smoke tomorrow morning
What's inside?
1. Althea Gets High (😉) Stock Price 📈
2. NZ sort of gets home grow 🌱
3. Photos of People (or Cats) Surrounded by Cannabis 📸
4. MGC Pharma goes to the UK 🇬🇧
Be the first to know and let us send you an email when The Greenfields News posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Just rolled tomorrows The Greenfields News... What's inside? 1. Cann Group’s growing revenues 📈 2. Emyria shares drop 12.00% after raising $2.5 million 📉 3. Little Green Pharma grows operating losses to $10 million 💰 4. Avecho partnerships jump shares 12.00% 🦘 Lots of quarterly reports to go over... We hope you are excited
Did you sign up for The Greenfields but can't find todays email? Check your promotions or spam folder Make sure you move it into your primary inbox so you get it next time:
💊 NSW's new Premier Chris Minns has shown a willingness to shift his stance on cannabis law reform based on changing circumstances. In the past, he defended legalizing recreational cannabis as a way to reduce organized crime and promote safer use. However, he later abandoned this idea before the upcoming election in 2023. Minns' latest update on his views is that the widespread availability of medicinal cannabis has opened up new avenues for pain relief and symptom management. He seems to be keeping an open mind about re-examining cannabis reform, so we'll be waiting to see how this develops. #medicinalcannabis #druglawreform #NSWpol
Just packed tomorrows newsletter We weren't clever enough to come up with something clever for 420, so you just got a bit extra tomorrow: 1. NSW Premier chicken on drug law reform 🐣 2. Will Cann Group ever reach positive cashflow? 💸 3. Photos of People (or Cats) Surrounded by Cannabis 📸 4. Creso Pharma positive Canada cashflow 🇨🇦 5. Who started 420? 4️⃣ 2️⃣ 0️⃣
When it's Tuesday morning and everyone else is reading The Greenfields newsletter except you because you didn't subscribe 👇
Good morning. We hope you are enjoying this mornings The Greenfields Didn't get yours? Check your promotions inbox:
Good morning. We had some hiccups with the newsletter scheduling this morning, but it should be in your inbox by now. If you can't find it, don't forget to check your spam and promotions folders:
🌿 Good morning everyone. We hope you are enjoying the latest edition of The Greenfields If you can't find it check your promotions and spam folders.
The latest The Greenfields should be in your inbox if you are a subscriber If you aren't seeing it, check your spam or promotions tabs:
Wondering what happened to your Greenfields Newsletter yesterday? Check your promotions or spam folder in gmail and drag it into the primary inbox so you get it next time
Want your business to be the top-listed Media Company?
